Baird Financial Group’s Barinthus Biotherapeutics BRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $179K | Buy |
192,461
+100,000
| +108% | +$93K | ﹤0.01% | 1717 |
|
|
2025
Q1 | $89.9K | Hold |
92,461
| – | – | ﹤0.01% | 1724 |
|
|
2024
Q4 | $112K | Hold |
92,461
| – | – | ﹤0.01% | 1714 |
|
|
2024
Q3 | $110K | Sell |
92,461
-175,244
| -65% | -$209K | ﹤0.01% | 1702 |
|
|
2024
Q2 | $375K | Buy |
267,705
+100,000
| +60% | +$140K | ﹤0.01% | 1485 |
|
|
2024
Q1 | $399K | Sell |
167,705
-28,591
| -15% | -$68K | ﹤0.01% | 1466 |
|
|
2023
Q4 | $724K | Hold |
196,296
| – | – | ﹤0.01% | 1235 |
|
|
2023
Q3 | $607K | Hold |
196,296
| – | – | ﹤0.01% | 1266 |
|
|
2023
Q2 | $404K | Buy |
196,296
+17,000
| +9% | +$35K | ﹤0.01% | 1422 |
|
|
2023
Q1 | $402K | Buy |
179,296
+86,835
| +94% | +$195K | ﹤0.01% | 1398 |
|
|
2022
Q4 | $217K | Buy |
+92,461
| New | +$217K | ﹤0.01% | 1578 |
|